ClinicalTrials.gg
RecruitingNCT05517980Updated Nov 3, 2026

Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of KP104 to Treat Glomerulonephritis

A Phase 2 interventional study of KP104 in Glomerulonephritis, sponsored by Kira Pharmacenticals (US), LLC.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-03.

Primary conditionGlomerulonephritis, IGARegistry: GlomerulonephritisReclassifiedWhy we changed it
Registry
Glomerulonephritis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Glomerulonephritis, IGA
Why
  1. The study's title name Glomerulonephritis, IGA, a narrower term within Glomerulonephritis.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Kira Pharmacenticals (US), LLC. · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Nov 3, 2026Now RecruitingFirst site in China+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 127 studies in Glomerulonephritis, IGA with a site in China — 57 open to participants now, 73 under way, 20 of them phase 3. Glomerulonephritis, IGA · China.

Planned enrollment
67th of 109
52 · median 84
Started
2025
with 19 others
Phase 2
27 of 127
14 open now
Primary completion
2028-12
later than 56 of 72 live
Registered
54th of 127
by date

Among the 127 studies in Glomerulonephritis, IGA with a site in China, this one is the 67th largest by planned enrollment of the 109 interventional ones that give a count, is one of 20 that started in 2025, is one of 27 in phase 2, reaches primary completion later than 56 of the 72 other live ones, and was the 54th registered.

Glomerulonephritis, IGA

277 studies on the registry are indexed under Glomerulonephritis, IGA; 108 are open to participants now.

Browse Glomerulonephritis, IGA studies →

Open to participants now

57 of the 127 studies in Glomerulonephritis, IGA with a site in China are open now. Recruiting first, the newest first:

51 more — sign in →

All 57 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 69 Glomerulonephritis, IGA studies recruiting now, 40 (58%) set no upper age limit and 24 (35%) stop at 75 or younger; 21 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies in Glomerulonephritis, IGA with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of KP104 in participants with IgAN and C3G. The study will start with enrolling the IgAN cohort. Approximately 42 participants with IgAN will be enrolled in 2 stages: Stage 1 will be used to collect safety, immunogenicity, PK, and PD data to select the optimal biologic dose (OBD) of KP104 for IgAN, as well as to preliminarily explore the effect of KP104 on C3G. Stage 2 will be used to collect safety, immunogenicity, PK, PD, and efficacy data at the OBD dose of KP104 for IgAN and C3G. As soon as the OBD for IgAN is determined, eligible participants with C3G will be enrolled and dosed at the OBD for IgAN for a minimum of 48 weeks for weekly maintenance dosing and a minimum of 47 weeks for biweekly maintenance dosing. Approximately 10 participants with C3G will be enrolled.

03

Conditions studied

  • Glomerulonephritis

Browse trials for

Keywords

  • KP104
  • Immunoglobulin A Nephropathy
  • Compliment-mediated Glomerulonephritis
  • Complement Inhibitor
04

In context

Glomerulonephritis, IGA Reclassified

277 studies on the registry are indexed under Glomerulonephritis, IGA; 108 are open to participants now.

This study's planned enrollment of 52 is below the median of 62 across 222 interventional studies indexed under Glomerulonephritis, IGA.

Browse Glomerulonephritis, IGA studies →

Lead sponsor

Kira Pharmacenticals (US), LLC. is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Compared within Glomerulonephritis, IGA, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Glomerulonephritis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Weight of >35 kilograms (kg) at Screening
  • (BMI) of \<35 kilograms per square meter (kg/m\^2)
  • UPCR >1.0 grams per gram (g/g) by 24-hour urine collection at Screening
  • Documented diagnosis and clinical status of IgAN or C3G as follows:

IgAN:

  • Diagnosis of IgAN verified by taken within the past 3 years prior to enrolment.
  • On stable regimen of angiotensin converting enzyme or angiotensin blocking agents for 12 weeks and/or sodium-glucose cotransporter-2 (SGLT2) inhibitors for 6 weeks at Screening

C3G:

  • Diagnosis of C3G verified by biopsy taken within the past 3 years prior to enrolment.
  • On stable regimen of angiotensin converting enzyme or angiotensin blocking agents for 12 weeks and/or SGLT2 inhibitors for 6 weeks at Screening

    • Females of and males must practice effective from Screening until 28 days after the end of study (EOS) visit.
    • Females of childbearing potential must have a negative pregnancy test at Screening and within 1 day prior to dosing of study drug

Exclusion criteria

Exclusion Criteria:

  • Any , poorly controlled underlying illness other than IgAN or C3G, as determined by the investigator
  • Treatment of any infection with IV (within 30 days of Screening) or oral (within 14 days of Screening) antibiotics, antivirals, or antifungals
  • History of infections with encapsulated organisms
  • History of untreated tuberculosis
  • Positive serology for virus (HCV) ribonucleic acid (RNA) or (HIV) at Screening
  • History of bone marrow or stem cell transplantation
  • (ANC) \<500 cells per microliter (cells/μL)
  • \<30 milliliters per minute per 1.73 square meter (mL/min/1.73 m\^2) using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula
  • Presence of crescent formation in >50 percent (%) of glomeruli assessed on renal
  • Nephrotic syndrome defined as presence of substantial proteinuria (> 3.5 g/24 hours), hypoalbuminemia (\< 30 grams per liter [g/L]), and edema/hyperlipidemia. Nephrotic range proteinuria alone is acceptable.
  • Rapidly progressive glomerulonephritis, defined as a fall in eGFR of > 30 mL/min/1.73 m\^2 within 24 weeks prior to the Screening Visit
  • Receiving renal replacement therapy or anticipated to require renal replacement therapy during the duration of the study

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
52 participants (estimated)

Study arms

  • Experimental
    IgAN Cohort Stage 1 Dose 1

    Participants will be randomized to receive weekly or biweekly maintenance doses of KP104 at Dose 1. Participants in Stage 1 will also have the opportunity to be switched to the OBD if they are still in the treatment period.

    Drug: KP104

  • Experimental
    C3G Cohort Stage 1 Dose 1

    Participants will be randomized to receive weekly or biweekly maintenance doses of KP104 at Dose 1. Participants in Stage 1 will also have the opportunity to be switched to the OBD if they are still in the treatment period.

    Drug: KP104

  • Experimental
    IgAN Cohort Stage 1 Dose 2

    Participants will be randomized to receive weekly or biweekly maintenance doses of KP104 at Dose 2. Participants in Stage 1 will also have the opportunity to be switched to the OBD if they are still in the treatment period.

    Drug: KP104

  • Experimental
    C3G Cohort Stage 1 Dose 2

    Participants will be randomized to receive weekly or biweekly maintenance doses of KP104 at Dose 2. Participants in Stage 1 will also have the opportunity to be switched to the OBD if they are still in the treatment period.

    Drug: KP104

  • Experimental
    IgAN Cohort Stage 2

    Participants will receive weekly or biweekly maintenance doses of KP104 at the OBD.

    Drug: KP104

  • Experimental
    C3G Cohort Stage 2

    Participants will receive weekly or biweekly maintenance doses of KP104 at the OBD.

    Drug: KP104

Interventions

07

What researchers measure

Primary outcomes

  1. Percent change from Baseline in 24-hour urinary protein creatinine ratio (UPCR) at Week 24 (C3G) for participants in Stage 2

    The UPCR will be calculated as percent change in protein (Pr)/ Creatinine (Cr).

    Time frame: Baseline and at Week 24

Secondary outcomes

  1. Number of participants reporting Treatment-Emergent Adverse Events (TEAEs)

    An adverse event (AE) is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease or any worsening of a pre-existing condition temporally associated with the use of a study drug, whether or not related to study drug. A TEAE is defined as any AE that started or worsened in severity on or after the first dose of study treatment.

    Time frame: Up to 56 Weeks

  2. Number of participants reporting Treatment-Emergent Serious Adverse Events (TESAEs)

    A TESAE is defined as a serious AE (SAE) that started or worsened in severity on or after the first dose of study treatment.

    Time frame: Up to 56 Weeks

  3. Number of participants reporting AEs of Special Interest (AESIs)

    An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease or any worsening of a pre-existing condition temporally associated with the use of a study drug, whether or not related to study drug. Number of participants with AESIs including infections and local or systemic administration reactions will be assessed.

    Time frame: Up to 56 Weeks

  4. Maximum concentration (Cmax) of KP104

    Blood samples will collected at indicated timepoints to assess Cmax.

    Time frame: At Baseline (Day 1), Days 8, 15, 22, 29, 43, 57, 85, 169, 253, 337, 365 and 395

  5. Trough concentration (Ctrough) of KP104 at steady state

    Blood samples will collected at indicated timepoints to assess Ctrough.

    Time frame: At Baseline (Day 1), Days 8, 15, 22, 29, 43, 57, 85, 169, 253, 337, 365 and 395

  6. Change from Baseline in estimated glomerular filtration rate (eGFR) at Week 24 (C3G) for participants in Stage 2

    Time frame: Baseline and at Week 24

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2028, 36 months after the start.

Of 41 phase 2 interventional studies under Glomerulonephritis, IGA, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 50. This study's planned 36 months is close to that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 3, 2026: start Mar 2025 → Dec 2025, primary completion Mar 2026 → Dec 2028 and completion Apr 2027 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2022
First posted
Aug 26, 2022
StartActual
Dec 1, 2025was Mar 2025
Primary completionEst.
Dec 2028was Mar 2026
CompletionEst.
Dec 2028was Apr 2027
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 3, 2026
Sites
1 site added — first site in China
Show site
  • Peking University First Hospital · Beijing, China
Nov 3, 2026
Start date
Mar 2025→Dec 1, 2025 (actual)
Nov 3, 2026
Primary completion
Mar 2026→Dec 2028
Nov 3, 2026
Study completion
Apr 2027→Dec 2028
Nov 3, 2026
Contact
Study contact's phone or email changed: none listed→•••1400. See the current contact
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in China
    Show site
    • Peking University First Hospital · Beijing, China
    Start date Mar 2025→Dec 1, 2025 (now actual)
    Primary completion Mar 2026→Dec 2028
    Study completion Apr 2027→Dec 2028
    Contact Study contact's phone or email changed: none listed→•••1400. See the current contact
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05517980
Lead sponsor
Kira Pharmacenticals (US), LLC.
Responsible party
Sponsor
First posted
Aug 26, 2022
Start date
Dec 1, 2025
Primary completion
Dec 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Nov 3, 2026

Study contacts

Study Director
Contact
privacy@kirapharma.com
650-549-1400

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vensobafusp alfa

Start the discussion